CytomX Therapeutics CTMX Cash ratio
Cash ratio at other companies
Other financials
Where this comes from
Calculated from CytomX Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's cash ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's cash ratio?
- CytomX Therapeutics (CTMX) reported cash ratio of 0.8× in Q1 2026.
- How has CytomX Therapeutics's cash ratio changed year-over-year?
- CytomX Therapeutics's cash ratio decreased by 10.7% year-over-year, from 0.9× to 0.8×.
- What is the long-term trend for CytomX Therapeutics's cash ratio?
- Over 5 years (2020 to 2025), CytomX Therapeutics's cash ratio has grown at a -37.4% compound annual growth rate (CAGR), from 2.8× to 0.3×.
- What does cash ratio mean?
- Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.